The IL-33/ST2 pathway contributes to intestinal tumorigenesis in humans and mice

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Mertz, Kirsten D ^a   Mager, Lukas F ^b   Wasmer, Marie Hélène ^b   Thiesler, Thore ^c   Koelzer, Viktor H ^b   Ruzzante, Giulia ^d   Joller, Stefanie ^d   Murdoch, Jenna R ^d   Brümmendorf, Thomas ^d   Genitsch, Vera ^b   Lugli, Alessandro ^b   Cathomas, Gieri ^a   Moch, Holger ^e   Weber, Achim ^e   Zlobec, Inti ^b   Junt, Tobias ^d   Krebs, Philippe ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Colorectal cancer; IL 33; Inflammation; Mouse model; ST2; Tissue microarray; Tumor microenvironment

Indexed keywords

GLYCOPROTEIN P 15095; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 33; INTERLEUKIN 6; LIPOPOLYSACCHARIDE;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STIMULATION; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PERMEABILITY BARRIER; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR INVASION;

EID: 84954459145     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1062966     Document Type: Article

References (45)

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383:1490-502; PMID:24225001; http://dx. doi. org/10. 1016/S0140-6736 (13)61649-9
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. The New England journal of medicine 1988; 319:525-32; PMID:2841597; http://dx. doi. org/ 10. 1056/NEJM198809013190901
3. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6:479-507; PMID:21090969; http://dx. doi. org/10. 1146/annurevpathol-011110-130235
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx. doi. org/ 10. 1016/j. cell. 2010. 01. 025
5. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228-33; PMID:2215606; http://dx. doi. org/10. 1056/NEJM 199011013231802
6. Jess T, GamborgM, Matzen P, MunkholmP, Sorensen TI. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of populationbased cohort studies. Am J Gastroenterol 2005; 100:2724-9; PMID:16393226; http://dx. doi. org/10. 1111/j. 1572-0241. 2005. 00287. x
7. Mudter J, NeurathMF. Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 2007; 13:1016-23; PMID:17476678; http://dx. doi. org/10. 1002/ibd. 20148
8. Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 2000; 7:133-8; PMID:10761792; http://dx. doi. org/10. 1007/s10434-000-0133-7
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http:// dx. doi. org/10. 1126/science. 1129139
10. Sedhom MA, Pichery M, Murdoch JR, Foligne B, Ortega N, Normand S, Mertz K, Sanmugalingam D, Brault L, Grandjean T et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 2013; 62:1714-23; PMID:23172891; http://dx. doi. org/10. 1136/gutjnl-2011-301785
11. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008; 180:2443-9; PMID:18250453; http://dx. doi. org/10. 4049/ jimmunol. 180. 4. 2443
12. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10:103-10; PMID:20081870; http://dx. doi. org/10. 1038/nri2692
13. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, Girard JP. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol 2012; 188:3488-95; PMID:22371395; http://dx. doi. org/ 10. 4049/jimmunol. 1101977
14. Kobori A, Yagi Y, Imaeda H, Ban H, Bamba S, Tsujikawa T, Saito Y, Fujiyama Y, Andoh A. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol 2010; 45:999-1007; PMID:20405148; http://dx. doi. org/10. 1007/s00535-010-0245-1
15. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007; 104:282-7; PMID:17185418; http://dx. doi. org/ 10. 1073/pnas. 0606854104
16. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/ Th2 driven enteritis. Proc Natl Acad Sci U S A 2010; 107:8017-22; PMID:20385815; http://dx. doi. org/10. 1073/pnas. 0912678107
17. Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis 2010; 16:1097-107; PMID:20014018; http:// dx. doi. org/10. 1002/ibd. 21175
18. Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, Nielsen OH. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett 2010; 128:80-5; PMID:19913053; http://dx. doi. org/10. 1016/j. imlet. 2009. 11. 001
19. Sponheim J, Pollheimer J, Olsen T, Balogh J, Hammarstrom C, Loos T, Kasprzycka M, Sorensen DR, Nilsen HR, Kuchler AM et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol 2010; 177:2804-15; PMID:21037074; http://dx. doi. org/10. 2353/ajpath. 2010. 100378
20. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, Nambu A, Abe T, Kiyonari H, Matsumoto K et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107:18581-6; PMID:20937871; http://dx. doi. org/10. 1073/pnas. 1003059107
21. Grobeta P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflamm Bowel Dis 2012; 18:1900-9; PMID:22508383; http://dx. doi. org/10. 1002/ibd. 22900
22. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2007; 2:1998-2004; PMID:17703211; http://dx. doi. org/10. 1038/nprot. 2007. 279
23. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009; 30:183-96; PMID: 19037092; http://dx. doi. org/10. 1093/carcin/bgn267
24. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA, Jr., Auxiliadora-Martins M, Basile-Filho A, McKenzie AN, Xu D, Cunha FQ et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16:708-12; PMID:20473304; http://dx. doi. org/10. 1038/nm. 2156
25. Jamieson T, Clarke M, Steele CW, Samuel MS, Neumann J, Jung A, Huels D, Olson MF, Das S, Nibbs RJ et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012; 122:3127-44; PMID:22922255; http://dx. doi. org/10. 1172/JCI61067
26. Gao Y, Li X, Yang M, Zhao Q, Liu X, Wang G, Lu X, Wu Q, Wu J, Yang Y et al. Colitis-accelerated colorectal cancer and metabolic dysregulation in a mouse model. Carcinogenesis 2013; 34:1861-9; PMID:23615396; http://dx. doi. org/10. 1093/carcin/bgt135
27. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15:103-13; PMID:19185845; http://dx. doi. org/10. 1016/j. ccr. 2009. 01. 001
28. Pollheimer J, Bodin J, Sundnes O, Edelmann RJ, Skanland SS, Sponheim J, Brox MJ, Sundlisaeter E, Loos T, Vatn M et al. Interleukin-33 drives a proinflammatory endothelial activation that selectively targets nonquiescent cells. Arterioscler Thromb Vasc Biol 2013; 33: e47-55; PMID:23162017; http://dx. doi. org/10. 1161/ATVBAHA. 112. 253427
29. Klimesova K, Kverka M, Zakostelska Z, Hudcovic T, Hrncir T, Stepankova R, Rossmann P, Ridl J, Kostovcik M, Mrazek J et al. Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis 2013; 19:1266-77; PMID:23567778; http:// dx. doi. org/10. 1097/MIB. 0b013e318281330a
30. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE et al. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491:254-8; PMID:23034650; http:// dx. doi. org/10. 1038/nature11465
31. Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 2011; 11:451-64; PMID:21247378; http://dx. doi. org/ 10. 2174/156800911795538066
32. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 2011; 187:1609-16; PMID:21734074; http://dx. doi. org/ 10. 4049/jimmunol. 1003080
33. Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 2013; 231:180-9; PMID:23775566; http://dx. doi. org/10. 1002/ path. 4226
34. Hu LA, Fu Y, Zhang DN, Zhang J. Serum IL-33 as a diagnostic and prognostic marker in non-small cell lung cancer. Asian Pac J Cancer Prev 2013; 14:2563-6; PMID:23725175; http://dx. doi. org/10. 7314/ APJCP. 2013. 14. 4. 2563
35. Sun P, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011; 56:3596-601; PMID:21643739; http://dx. doi. org/10. 1007/s10620-011-1760-5
36. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W, Qin Q. IL-33/ST2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 2014; 453(3):486-92; PMID:25280997; http:// dx. doi. org/10. 1016/j. bbrc. 2014. 09. 106
37. Cui G, Qi H, Gundersen MD, Yang H, Christiansen I, Sorbye SW, Goll R, Florholmen J. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer. Cancer Immunol Immunother 2014; 64(2):181-90; PMID:25324197; http://dx. doi. org/10. 1007/s00262-014-1624-x
38. Huang JR, Tsai YC, Chang YJ, Wu JC, Hung JT, Lin KH, Wong CH, Yu AL. alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3. J Immunol 2014; 192:1972-81; PMID:24465013; http://dx. doi. org/10. 4049/ jimmunol. 1302623
39. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, Lukic ML. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014; 134:1669-82; PMID:24105680; http://dx. doi. org/10. 1002/ ijc. 28481
40. Schiering C, Krausgruber T, Chomka A, Frohlich A, Adelmann K, Wohlfert EA, Pott J, Griseri T, Bollrath J, Hegazy AN et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 2014; 513(7519):564-8; PMID:25043027; http://dx. doi. org/10. 1038/ nature13577
41. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L. High frequency of tumorinfiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 2010; 126:2635-43; PMID:19856313; http://dx. doi. org/10. 1002/ijc. 24989
42. Rossle M, Sigg M, Ruschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. Virchows Arch 2013; 463:623-31; PMID:24085553; http://dx. doi. org/10. 1007/s00428-013-1492-3
43. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7; PMID:9662379; http://dx. doi. org/ 10. 1038/nm0798-844
44. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000; 191:1069-76; PMID:10727469; http://dx. doi. org/10. 1084/ jem. 191. 6. 1069
45. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, Signori E, Fazio VM. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog 2011; 10:9; PMID:21483655; http://dx. doi. org/10. 4103/ 1477-3163. 78279